The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab

Sukgen, Emine Alyamaç; Çömez, Ayşegül; Koçluk, Yusuf; Cevher, Selim

doi:10.1159/000449530

Cited by 29 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall treatment outcomes in APROP have been reported to be worse than staged ROP, while recurrence of retinopathy or plus disease has been more common and earlier with the use of Ranibizumab than Bevacizumab. [ 8 15 22 23 ] Nevertheless we believe, 96.7% favorable outcome in eyes with APROP has not been previously reported. Yoon et al .…”

Section: Discussionmentioning

confidence: 66%

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity

Gangwe¹,

Agrawal

Gangrade³

et al. 2021

Indian J Ophthalmol

View full text Add to dashboard Cite

Purpose: The aim of this study was to report the treatment outcomes of early and deferred laser in infants of aggressive posterior retinopathy of prematurity (APROP) after initial treatment with intravitreal Ranibizumab (IVR). Methods: In a prospective, randomized, interventional study, infants with APROP received IVR (0.25 mg) and were randomized into two groups prior to laser. Laser was done at 1 week (group 1) or at 6 weeks or earlier if there was a recurrence of plus disease (group 2). The structural outcome, number of laser spots, duration of laser procedure and refractive error at 6 months were compared. Favorable structural outcome was defined as, complete regression of disease at 6 weeks after laser. Results: 63 eyes of 32 infants with APROP were enrolled. Mean gestational age (GA) and birth weight (BW) were 30.2 ± 2.3 weeks and 1294 ± 372.8 grams respectively. GA, BW, and disease severity were comparable at baseline. 27 (90%) eyes in group 1 and 29 (93.5%) eyes in group 2 had favorable structural outcome ( P = 0.61) at 6 weeks after laser. Eyes in group 2 (2149.8 ± 688.7) required lesser number of laser spots than group 1 (2570.8 ± 615) ( P = 0.01). At six months, more eyes in group 1 had myopic refractive error (Mean spherical equivalent: –1.0D ± 1.3) than those in group 2 (Mean spherical equivalent: 0.5D ± 1.9) ( P = 0.002). Conclusion: Infants with APROP receiving IVR have comparable structural outcomes after an early or deferred laser. Moreover, eyes undergoing deferred laser require less number of laser spots and have a less myopia at 6 months after laser.

show abstract

Section: Discussionmentioning

confidence: 66%

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity

Gangwe¹,

Agrawal

Gangrade³

et al. 2021

Indian J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Vascular endothelial growth factor (VEGF) is necessary in the newborn for normal retinal vascularization. A previous study found that anti‐VEGF therapy could delay peripheral retinal vascularization in ROP (Alyamac Sukgen et al, 2016). The rate of retinal vascularization was 48.18% with ranibizumab and 45.71% with conbercept in Zone I ROP and APROP and 71.41% with ranibizumab and 76.21% with conbercept in Zone II ROP.…”

Section: Discussionmentioning

confidence: 97%

“…This result is consistent with the findings of a previous study. In Sukgen’s study, 26% of the infants receiving ranibizumab and 18% of the patients receiving bevacizumab had remaining avascular areas (Alyamac Sukgen et al, 2016). In Tahija’s study, approximately, 55% of the eyes treated had remaining avascular areas.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity

Cheng

Zhu

Linghu

et al. 2020

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose To compare the effectiveness of intravitreal conbercept and ranibizumab treatment for retinopathy of prematurity (ROP). Methods In this retrospective study, the date of patients with ROP treated with intravitreal conbercept or ranibizumab from July 2012 to March 2018 with at least 12 months of follow‐up at the Eye Center in People’s Hospital of Peking University were analysed. Regression, progression or recurrence and peripheral retina vascularization were evaluated. Results In total, 283 eyes (145 infants) with conbercept treatment and 916 eyes (480 infants) with ranibizumab treatment were enrolled. In zone I ROP and aggressive posterior ROP (APROP), the recurrence prevalence was 49.09% (108/220 eyes) and 28.57% (10/33 eyes), and the recurrence interval was 7.87 ± 0.65 (5.5–9.5) weeks and 10.6 ± 1.53 (10.5–13) weeks in the ranibizumab and conbercept groups, respectively. In zone II ROP disease, the recurrence prevalence was 23.56% (164/696 eyes) and 13.31% (33/248 eyes), and the interval of recurrence was 8.40 ± 0.88 (6–10.5) weeks and 11.4 ± 1.35 (11–13.5) weeks in the ranibizumab and conbercept groups, respectively. The recurrence prevalence was significantly higher with ranibizumab in Zone I ROP and APROP (p = 0.006) and Zone II ROP (p < 0.001), and the recurrence interval was significantly longer in the conbercept group than that in the ranibizumab (p < 0.001). There was no significant difference in the rate of retinal vascularization (p = 0.441). Conclusion Conbercept and ranibizumab are effective for treating ROP. Compared with ranibizumab, conbercept resulted in less recurrence and longer treatment intervals.

show abstract

“…Ranizumab (Lucentis) is becoming more prominent following an increasing number of articles and trials demonstrating treatment success, with evidence of shorter duration of systemic VEGF suppression. Question marks remain for both drugs regarding optimal dosing and follow-up because of relatively high retreatment rates with laser or re injection, particularly for ranizumab (Lucentis) 9 17 18. These drugs are extremely effective in treating the most aggressive and posterior forms of ROP.…”

Section: Discussionmentioning

confidence: 99%

Contralateral effect of systemic absorption of low dose bevacizumab (Avastin) after unilateral intravitreal injection in severe retinopathy of prematurity (ROP)

2020

View full text Add to dashboard Cite

An extremely premature baby boy born at 23 weeks’ gestational age was treated with unilateral low dose of 0.16 mg/0.025 mL intravitreal bevacizumab in the left eye for aggressive retinopathy of prematurity (ROP). He developed photographically documented changes in his contralateral right eye on imaging 5 days later. Second eye treatment was at 12 days. He has development assessment and ophthalmic review beyond age 2, which is normal. Systemic absorption of the drug caused an end organ effect to slow down and reverse ROP in his untreated right eye. Both eyes vascularised fully. His normal Bayley III developmental score at age 2 is uncommon for a 23-week gestation baby. Even at a low dose, bevacizumab has the potential for end organ effect on the second eye, and therefore other organs. In this case, there are no medium-term measurable neurodevelopmental side-effects. We suggest longer term follow-up is required before excluding unwanted side-effects.

show abstract

The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab

Cited by 29 publications

References 32 publications

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity

Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity

Contralateral effect of systemic absorption of low dose bevacizumab (Avastin) after unilateral intravitreal injection in severe retinopathy of prematurity (ROP)

Contact Info

Product

Resources

About